

NAVIGATE SAFELY TOWARDS EUGLYCEMIA

Start with

Reclimet[®] XR

Extended Release Gliclazide 60 mg & Metformin Hydrochloride 500 mg Scored Tablets

Add on

Reclide[™] XR

Extended Release Gliclazide 60 mg Scored Tablets

INTRODUCTION

- Oral antidiabetic drugs (OADs) still dominate the prescribing pattern for management of T2DM
- For decades, SUs have been important drugs in the antidiabetic therapeutic armamentarium
- SUs alone or in combination with metformin have been the most commonly prescribed OADs
- Unlike conventional SUs, modern SUs such as Gliclazide MR & Glimepiride are associated with better safety profiles
- Individualization of treatment, using SUs in combination with other drugs, backed with careful monitoring and patient education, ensures maximum benefits with minimal side effects


EFFICACY OF ORAL ANTIHYPERGLYCEMIC AGENTS

| OAD | Expected decrease in A1C with monotherapy (%) |
|---------------------------------|---|
| Metformin | 1 - 2% |
| Sulfonylurea | 1 - 2% |
| TZDs | 0.5 - 1.4% |
| α -Glucosidase Inhibitor | 0.5 - 0.8% |
| Glinide | 0.5 - 1.5% |
| DPP-4i | 0.5 - 0.9% |
| SGLT2-I | 0.5 - 0.9% |

EFFICACY AS A COMBINATION THERAPY

| Regimen | HbA1c reduction (%) |
|--|----------------------------|
| Sulfonylurea + metformin | 1.7 |
| Sulfonylurea + rosiglitazone | 1.4 |
| Sulfonylurea + pioglitazone | 1.2 |
| Sulfonylurea + acarbose | 1.3 |
| Repaglinide + metformin | 1.4 |
| Pioglitazone + metformin | 0.7 |
| Rosiglitazone + metformin | 0.8 |
| Dipeptidyl peptidase 4 inhibitor + metformin | 0.7 |
| Dipeptidyl peptidase 4 inhibitor + pioglitazone | 0.7 |


GLYCEMIC CONTROL WITH GLICLAZIDE XR



A model-based meta-analysis of 229 studies; n=1,21,914


GUIDE STUDY: GLICLAZIDE MR VS GLIMEPIRIDE

Mean HbA_{1c} change from Baseline to Week 27



Gliclazide MR is at least as effective as Glimepiride
(1.2% vs 1%)

ΔHbA1c IN INTENSIVE ARM OVER 5 YEARS - ADVANCE



NAVIGATE SAFELY TOWARDS EUGLYCEMIA WITH OPTIMAL TREATMENT CHOICE

For uncontrolled T2DM patients with HbA1c >7.5%

Start with

Reclimet[®] XR

Extended Release Gliclazide 60 mg & Metformin Hydrochloride 500 mg Scored Tablets

Obese & Overweight, Start with

Reclimet[®] XR Forte

Gliclazide and Metformin Hydrochloride Extended Release Tablets 60 + 1000 mg

Add on

Reclide[™] XR

Extended Release Gliclazide 60 mg Scored Tablets

Switch to

Reclimet[®] PG^{30/60}

Gliclazide Sustained Release 30/60 mg and Metformin Hydrochloride 500 mg and Pioglitazone 15 mg Tablets

For Dug-Naïve patients,

Twice-daily dosing

Semi Reclimet[®]

Gliclazide 40 mg and Metformin Hydrochloride 500 mg Tablets

One-daily dosing

Reclimet[®] OD30

Gliclazide Modified Release 30 mg and Metformin Hydrochloride 500 mg Tablets

SU - Sulfonylurea

T2DM - Type 2 Diabetes Mellitus

OAD - Oral anti diabetic drugs

HbA1c/A1c - Glycated haemoglobin A1c

TZD - Thiazolidinediones

DPP4-I - DPP4 inhibitors

SGLT2-I - SGLT2 inhibitors



Further information available on request from:

Dr. Reddy's Laboratories Ltd. 7-1-27, Ameerpet, Hyderabad - 500016. Andhra Pradesh,
India. www.drreddys.com

GGI-CO-CH-MAX-300023080-300023080-LB-F21-411